IP Library Granted Patent US 12,376,750
Granted Patent B2
US 12,376,750 · App. 18/495,821 · Granted Aug 5, 2025

Tumor characterization and outcome prediction through quantitative measurements of tumor-associated vasculature

Inventors: Anant Madabhushi (Shaker Heights, OH); Nathaniel Braman (Bethel Park, PA)
Assignees: Case Western Reserve University; The United States Government as Represented by The Department of Veteran Affairs
A61B5/02007A61B5/0035A61B5/004A61B5/08A61B5/7267A61B5/7275G06T7/0012G06T7/12G06T2207/10081G06T2207/10088G06T2207/20036G06T2207/20081G06T2207/30061G06T2207/30068G06T2207/30096G06T2207/30101
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,376,750
App. No.
18/495,821
Granted
Aug 5, 2025
Kind
B2
Abstract

The present disclosure relates to a method. The method may be performed by accessing data derived from one or more routine clinical medical imaging scans including a lesion in which the lesion and associated vasculature are segmented in a three-dimensional segmentation. At least two features are extracted from the three-dimensional segmentation of the associated vasculature. The at least two features include at least one feature indicative of a morphology of the associated vasculature or a portion thereof, and at least one feature indicative of a function of the associated vasculature or a portion thereof. The at least two features, and/or one or more statistics of the at least two features, are provided to a machine learning model trained to make a prediction concerning the lesion. The prediction concerning the lesion is received from the machine learning model.

Claims (37)

1. A method, comprising:

accessing data derived from one or more routine clinical medical imaging scans including a lesion in which the lesion and associated vasculature are segmented in a three-dimensional segmentation;

extracting at least two features, the at least two features including at least one feature indicative of a morphology of the associated vasculature or a portion thereof, and at least one feature indicative of a function of the associated vasculature or a portion thereof, the at least one feature indicative of the morphology extracted from the three-dimensional segmentation of the associated vasculature, and the at least one feature indicative of the function being a pharmacokinetic measurement extracted from a region of tissue in the one or more routine clinical imaging scans that is perfused by the associated vasculature;

providing the at least two features, and/or one or more statistics of the at least two features, to a machine learning model trained to make a prediction concerning the lesion; and

receiving, from the machine learning model, the prediction concerning the lesion.

2. The method of claim 1 , wherein the prediction concerning the lesion comprises one of a predicted response to a treatment for the lesion or a prognosis for the lesion.

3. The method of claim 2 , wherein the prediction concerning the lesion concerns response to neoadjuvant chemotherapy for the lesion.

4. The method of claim 1 , wherein the at least one feature indicative of the morphology of the associated vasculature comprises one or more of a torsion per branch of a plurality of branches of the associated vasculature, a curvature standard deviation per branch of the plurality of branches, a mean curvature per branch, a maximum curvature per branch of the plurality of branches, a curvature skewness per branch of the plurality of branches, a curvature kurtosis per branch of the plurality of branches, a global vascular curvature, the torsion across the plurality of branches, a vessel volume, a vessel volume normalized to a volume of a region of interest comprising the lesion, a vessel volume normalized to a volume of the lesion, a total vessel length, a number of branches of the plurality of branches that enter the lesion, or a percentage of branches of the plurality of branches that enter the lesion.

5. The method of claim 1 , wherein the pharmacokinetic measurement comprises a measurement comprises a measurement of temporal contrast enhancement changes.

6. The method of claim 5 , wherein the pharmacokinetic measurement of temporal contrast enhancement changes comprises signal enhancement ratio, time to peak enhancement, rate of uptake, or rate of washout.

7. The method of claim 1 , wherein the machine learning model is one of, or an ensemble of two or more of, a logistic regression model, a Cox regression model, a Least Absolute Shrinkage and Selection Operator (LASSO) regression model, a naïve Bayes classifier, a support vector machine (SVM) with a linear kernel, a SVM with a radial basis function (RBF) kernel, a linear discriminant analysis (LDA) classifier, a quadratic discriminant analysis (QDA) classifier, a logistic regression classifier, a decision tree, a random forest, a diagonal LDA, a diagonal QDA, a neural network, an AdaBoost algorithm, an elastic net, a Gaussian process classification, or a nearest neighbors classification.

8. A non-transitory computer-readable medium storing computer-executable instructions that, when executed, cause a processor to perform the method of claim 1 .

9. An apparatus, comprising:

memory configured to store data derived from one or more routine clinical medical imaging scans including a lesion, wherein the lesion and associated vasculature are segmented in a three-dimensional segmentation; and

one or more processors configured to:

access the data derived from one or more routine clinical medical imaging scans including the lesion in which the lesion and the associated vasculature are segmented in the three-dimensional segmentation,

extract at least two features, the at least two features including at least one feature indicative of a morphology of the associated vasculature or a portion thereof, and at least one feature indicative of a function of the associated vasculature or a portion thereof, the at least one feature indicative of the morphology extracted from the three-dimensional segmentation of the associated vasculature, and the at least one feature indicative of the function being a pharmacokinetic measurement extracted from a region of tissue in the one or more routine clinical imaging scans that is perfused by the associated vasculature, and

provide the at least two features, and/or one or more statistics of the at least two features, to a machine learning model trained to make a prediction concerning the lesion.

10. The apparatus of claim 9 , wherein the at least one feature indicative of the morphology includes a feature describing a vessel orientation.

11. The apparatus of claim 9 , wherein the at least one feature indicative of the function includes a pharmacokinetic measurement of temporal contrast enhancement changes.

12. The apparatus of claim 9 , wherein the prediction relates to a response to neoadjuvant chemotherapy.

13. A method, comprising:

accessing data derived from one or more routine clinical medical imaging scans including a lesion in which the lesion and associated vasculature are segmented in a three-dimensional segmentation;

extracting at least one feature indicative of a spatial organization of the associated vasculature, the at least one feature taken from a projection onto a plane of at least a portion of the three-dimensional segmentation of the associated vasculature;

providing the at least one feature and/or at least one statistic of the at least one feature to a trained machine learning model; and

receiving, from the trained machine learning model, a prediction concerning the lesion.

14. The method of claim 13 , wherein the prediction concerning the lesion comprises one of a predicted response to a treatment for the lesion or a prognosis for the lesion.

15. The method of claim 14 , wherein the prediction concerns response to neoadjuvant chemotherapy for the lesion.

16. The method of claim 13 , wherein the at least one feature indicative of the spatial organization of the associated vasculature comprise one or more of a vessel orientation along a XY projection image, a vessel orientation along a XZ projection image, a vessel orientation along a YZ projection image, a vessel orientation along a rotation-elevation projection image, a vessel orientation along a distance-rotation projection image, or a vessel orientation along a distance-elevation projection image.

17. The method of claim 13 , further comprising:

extracting at least one feature indicative of a morphology of the associated vasculature; and

providing the at least one feature indicative of the spatial organization and the at least one feature indicative of a morphology and/or statistics thereof to the trained machine learning model.

18. The method of claim 17 , further comprising:

identifying branches of the associated vasculature in the three-dimensional segmentation;

wherein the at least one feature indicative of morphology is based, at least in part, on the branches of the associated vasculature.

19. The method of claim 17 , wherein the at least one feature indicative of the morphology comprises one or more of a torsion per branch of a plurality of branches of the associated vasculature, a curvature standard deviation per branch of the plurality of branches, a mean curvature per branch, a maximum curvature per branch of the plurality of branches, a curvature skewness per branch of the plurality of branches, a curvature kurtosis per branch of the plurality of branches, a global vascular curvature, the torsion across the plurality of branches, a vessel volume, a vessel volume normalized to a volume of a region of interest comprising the lesion, a vessel volume normalized to a volume of the lesion, a total vessel length, a number of branches of the plurality of branches that enter the lesion, or a percentage of branches of the plurality of branches that enter the lesion.

20. A non-transitory computer-readable medium storing computer-executable instructions that, when executed, cause a processor to perform the method of claim 13 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2023
From: MADABHUSHI, ANANT
To: CASE WESTERN RESERVE UNIVERSITY; THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERAN AFFAIRS
Reel/Frame 065366/0452 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2023
From: BRAMAN, NATHANIEL
To: CASE WESTERN RESERVE UNIVERSITY
Reel/Frame 065366/0456 →
Continuity (3)
Continuation 17116319 · Dec 9, 2020
Provisional Application 62945310 · Dec 9, 2019
Related Publication 20240057874A1 · Feb 22, 2024
References Cited (8)
US 20140301619A1 · Stavros et al. · 2014 [cited by applicant]
US 20170039737A1 · Madabhushi et al. · 2017 [cited by applicant]
US 20170193657A1 · Madabhushi et al. · 2017 [cited by applicant]
Braman, Nathaniel M., et al. “Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.” Breast Cancer Research 19 (201… [cited by examiner]
Jason Brownlee (How to Choose a Feature Selection Method for Machine Learning, www.machinelearningmastery.com/feature-selection-with-real-and-categorical-data/, Nov. 27, 2019). [cited by applicant]
Non-Final Office Action dated Dec. 22, 2022 for U.S. Appl. No. 17/116,319. [cited by applicant]
Final Office Action dated May 17, 2023 for U.S. Appl. No. 17/116,319. [cited by applicant]
Notice of Allowance dated Sep. 27, 2023 for U.S. Appl. No. 17/116,319. [cited by applicant]
Cited By (1)
US 12,657,704